Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Daliresp

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Roflumilast (Daliresp®, Daxas®) is a selective phosphodiesterase 4 (PDE4) inhibitor that decreases systemic and pulmonary… Expand
  • table 1
  • table 2
  • figure 1
2014
2014
Roflumilast therapy has a limited role in patients with severe COPD, and no role in patients with mild to moderate COPD. It will… Expand
2013
2013
Objective To identify the structure of the new drug daliresp. Methods The structure of daliresp w as identified by UV,IR,MS,1H… Expand
2013
2013
APIXABAN (ELIQUIS®) FOR ORAL ANTICOAGULATION IN NONVALVULAR ATRIAL FIBRILLATION hronic obstructive pulmonary disease (COPD) is a… Expand
  • table 1
  • table 1
  • table 4
Review
2013
Review
2013
PURPOSE The pharmacology, pharmacokinetics, efficacy, and safety of roflumilast-the first in a new class of agents for managing… Expand
2012
2012
  • J. Baye
  • P & T : a peer-reviewed journal for formulary…
  • 2012
  • Corpus ID: 30328613
Chronic obstructive pulmonary disease (COPD) is characterized by a gradual and progressive loss of lung function. The consensus… Expand
2012
2012
is substantial. Quality of life, morbidity, and mortality are all negatively affected by the disease. In the National Health and… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
2011
2011
  • The Medical letter on drugs and therapeutics
  • 2011
  • Corpus ID: 13234119
 
Review
2011
Review
2011
Roflumilast (Daxas® [EU], Daliresp® [USA]) is the first phosphodiesterase 4 inhibitor approved in Europe to be used in severe… Expand
2011
2011
roflumilast Chronic obstructive pulmonary disease (COPD) is a progressive, irreversible lung disease that is often associated… Expand